In the realm of aquaculture, particularly in the context of grass carp farming in China, the threat of Grass Carp Reovirus (GCRV) looms ominously, causing significant disruptions due to the associated Grass Carp hemorrhagic disease. As a beacon of hope in this scenario, vaccines have emerged as pivotal tools in safeguarding aquatic organisms against infectious onslaughts. Among these, the utilization of oral immunization with Lactobacillus casei stands out for its safety profile and high efficacy. This innovative vaccination approach offers a repertoire of benefits, including ease of administration and noninvasive delivery, revolutionizing the landscape of disease prevention in aquatic species.
The crux of this study delves into the development and application of an oral probiotic vaccine laden with Lactobacillus casei, aimed at bolstering the defense mechanisms of grass carp against GCRV infection. The foundation of this intervention lies in the creation of the recombinant LC-pVE5523-VP5, a fusion of the outer capsid protein VP5 of GCRV as the immunogen and pVE5523 as the secretory expression vector. Leveraging the prowess of vacuum freeze-drying technology, bacterial powder was meticulously prepared from the fermented broth. This dried bacterial formulation was skillfully amalgamated with feed, subsequently fashioned into pellets for seamless oral administration.
Upon the consumption of feed infused with the recombinant L.casei powder, a cascade of immune responses was triggered within the grass carp population. Evident through the significant upregulation of immune-related genes such as IFN I and IgM, the oral immunization regimen exhibited a profound impact on the host’s immune landscape. Furthermore, a temporal analysis unveiled a progressive surge in serum IgM levels with prolonged immunization periods, underscoring the sustained immunostimulatory effects of the vaccine. The crux of the efficacy assessment unfolded through a rigorous survival analysis post-GCRV challenge, illuminating a stark contrast in outcomes between the immunized group (with a commendable 74% survival rate) and the control cohort (with a meager 35% survival rate).
Delving deeper into the protective mechanisms, the investigation extended to scrutinize the viral replication dynamics within vaccine-treated fish. Remarkably, the findings unveiled a stark reduction in virus content within the fish tissue of the immunized cohort compared to their non-immunized counterparts, underscoring the robust antiviral shield conferred by the vaccine. Intriguingly, the persistence of LC-pVE5523-VP5 within the fish intestines even 15 days post-vaccination underscored the sustained immunomodulatory effects of the oral probiotic vaccine, fortifying the defense mechanisms against GCRV incursions.
In conclusion, the groundbreaking utilization of oral probiotic vaccines harnessed through the innovative amalgamation of Lactobacillus casei holds immense promise in fortifying the defense mechanisms of aquatic species against virulent pathogens like GCRV. This strategic advancement not only amplifies the arsenal of disease prevention strategies in aquaculture but also underscores the pivotal role of probiotic-based interventions in bolstering immune resilience in vulnerable populations. As we navigate the complex interplay between host-pathogen dynamics and immunomodulatory interventions, the saga of oral probiotic vaccines unfolds as a beacon of hope in the realm of aquatic health management, heralding a new era of disease control and prevention strategies.
- The strategic integration of oral probiotic vaccines laden with Lactobacillus casei offers a paradigm shift in fortifying defense mechanisms against GCRV infection in aquatic species.
- Immunization with the recombinant LC-pVE5523-VP5 triggers a robust immune response in grass carp, evidenced by the upregulation of key immune-related genes and sustained elevation of serum IgM levels.
- Survival analysis post-GCRV challenge accentuates the superior protective efficacy of the oral probiotic vaccine, with a significantly higher survival rate observed in the immunized cohort.
- The profound reduction in viral replication within the tissues of vaccine-treated fish underscores the potent antiviral shield conferred by the oral probiotic vaccine, signifying its pivotal role in disease mitigation strategies.
- The enduring presence of LC-pVE5523-VP5 within the fish intestines post-vaccination highlights the sustained immunomodulatory effects of the oral probiotic vaccine, enhancing the resilience of aquatic species against GCRV incursions.
Read more on pubmed.ncbi.nlm.nih.gov